Hyloris Pharmaceuticals SA Stock price

Equities

HYL

BE0974363955

Pharmaceuticals

Real-time Euronext Bruxelles 04:09:36 2024-02-23 am EST 5-day change 1st Jan Change
12 EUR -0.41% Intraday chart for Hyloris Pharmaceuticals SA -4.76% -5.88%
Sales 2023 * 7.35M 7.96M Sales 2024 * 24.3M 26.31M Capitalization 337M 365M
Net income 2023 * -9M -9.74M Net income 2024 * 1M 1.08M EV / Sales 2023 * 41.7 x
Net cash position 2023 * 31.1M 33.67M Net cash position 2024 * 19.3M 20.89M EV / Sales 2024 * 13.1 x
P/E ratio 2023 *
-20.1 x
P/E ratio 2024 *
-20.4 x
Employees 40
Yield 2023 *
-
Yield 2024 *
-
Free-Float 43.38%
More Fundamentals * Assessed data
Dynamic Chart
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse MT
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus CI
Hyloris Pharmaceuticals Wins US FDA's Orphan Drug Designation for Leukemia Treatment MT
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals CI
Hyloris Pharmaceuticals Partner Gets US FDA Nod for Warts Gel MT
Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada CI
Hyloris Pharmaceuticals’ Pain Relief Drug Gets US FDA Approval; Shares Jump MT
Hyloris Pharma wins US FDA approval for pain treatment RE
Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV CI
More news
1 day-2.03%
1 week-5.12%
Current month-9.06%
1 month-6.23%
3 months-4.37%
6 months+5.24%
Current year-5.49%
More quotes
1 week
12.00
Extreme 12
12.80
1 month
12.00
Extreme 12
13.30
Current year
12.00
Extreme 12
13.30
1 year
10.60
Extreme 10.6
14.10
3 years
10.60
Extreme 10.6
19.10
5 years
8.80
Extreme 8.8
19.10
10 years
8.80
Extreme 8.8
19.10
More quotes
Managers TitleAgeSince
Founder 50 11-12-31
Founder 48 11-12-31
Director of Finance/CFO 53 21-09-22
Members of the board TitleAgeSince
Director/Board Member 66 19-12-31
Director/Board Member 74 19-12-31
Director/Board Member 75 19-12-31
More insiders
Date Price Change Volume
24-02-23 12 -0.41% 1 502
24-02-22 12.05 -2.03% 7,707
24-02-21 12.3 -1.20% 5,894
24-02-20 12.45 -2.73% 3,674
24-02-19 12.8 +1.59% 5,723

Real-time Euronext Bruxelles, February 22, 2024 at 11:35 am EST

More quotes
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.05 EUR
Average target price
19.9 EUR
Spread / Average Target
+65.15%
Consensus

Annual profits - Rate of surprise

1st Jan change Capi.
-5.49% 365 M $
+32.03% 693 B $
+22.22% 552 B $
+2.37% 386 B $
+18.57% 328 B $
+14.05% 312 B $
-6.40% 209 B $
+6.72% 210 B $
-5.32% 197 B $
-4.31% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Hyloris Pharmaceuticals SA - Euronext Bruxelles
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer